keyword
MENU ▼
Read by QxMD icon Read
search

hcv infection dialysis

keyword
https://www.readbyqxmd.com/read/29718748/an-update-on-the-toxicological-considerations-for-protease-inhibitors-used-for-hepatitis-c-infection
#1
Lung-Yi Mak, Wai-Kay Seto, Ching-Lung Lai, Man-Fung Yuen
Hepatitis C virus protease inhibitors (PIs) are important components of many direct acting antiviral regimens. Many clinical trials and real-world studies have described the safety data for individual PIs. We aimed to review the safety of both the first and second generation PIs in patients with chronic hepatitis C (CHC). Areas covered: The unique pharmacokinetic properties of PIs partly explain their toxicities. Second generation PIs, when used without interferon and ribavirin, are well-tolerated. Use of PIs in renal impaired patients or those on dialysis appears to be safe...
May 2, 2018: Expert Opinion on Drug Metabolism & Toxicology
https://www.readbyqxmd.com/read/29694728/rationale-for-treatment-of-hepatitis-c-virus-infection-in-end-stage-renal-disease-patients-who-are-not-kidney-transplant-candidates
#2
REVIEW
Laith Al-Rabadi, Terry Box, Girish Singhania, Catreena Al-Marji, Adhish Agarwal, Isaac Hall, Craig E Gordon, Huy Tran
Hepatitis C virus (HCV) infection is a common problem in patients treated with maintenance hemodialysis (HD) and is associated with an increased morbidity and mortality and lower quality of life. The major causes of HCV-associated mortality are liver and cardiovascular-related death. HCV-infected HD patients have a higher prevalence of inflammation-related metabolic and vascular diseases, leading to high rates of cardiovascular mortality in patients with end-stage renal disease. In the current era of highly effective direct-acting antiviral regimens, HCV treatment may also confer hepatic, cardiovascular and other morbidity and mortality benefits even to dialysis-dependent patients who do not qualify for kidney transplantation...
April 2018: Hemodialysis International
https://www.readbyqxmd.com/read/29694722/transplantation-of-hepatitis-c-virus-infected-kidneys-into-hepatitis-c-virus-uninfected-recipients
#3
REVIEW
Meghan E Sise, Donald F Chute, Jenna L Gustafson, David Wojciechowski, Nahel Elias, Raymond T Chung, Winfred W Williams
Long wait times for kidney transplant and the high risk of mortality on dialysis have prompted investigation into strategies to increase organ allocation and decrease discard rates of potentially viable kidneys. Organs from hepatitis C virus (HCV) antibody positive donors are often rejected; nearly 500 HCV-infected kidneys are discarded annually in the United States. Due the opioid epidemic, the number of HCV-infected donors has increased because of a rise in both new HCV infections and drug-related deaths...
April 2018: Hemodialysis International
https://www.readbyqxmd.com/read/29676846/generic-sofosbuvir-based-direct-acting-antivirals-in-hepatitis-c-virus-infected-patients-with-chronic-kidney-disease
#4
Manoj Kumar Sharma, Suman Lata Nayak, Ekta Gupta, Ashish Kataria, Shiv K Sarin
BACKGROUND & AIMS: There is scant data on use of sofosbuvir containing directly acting anti-viral (DAA) regimens in chronic kidney disease (CKD) patients. Recently generic versions of DAAs have become available in low income countries including India. The aim of this study was to study the efficacy and safety of generic sofosbuvir in combination with generic ribavirin, ledipasvir, or daclatasvir in HCV infected patients with CKD including patients with advanced CKD (CKD stage 4 or 5 with an estimated glomerular filtration rate (GFR) <30 mL/min or those on dialysis)...
April 20, 2018: Liver International: Official Journal of the International Association for the Study of the Liver
https://www.readbyqxmd.com/read/29624804/dialysis-facility-screening-and-testing-practices-in-the-era-of-improved-hepatitis-c-treatment
#5
Miranda S Moore, Angelica Bocour, Ann Winters
Patients receiving hemodialysis are at increased risk of hepatitis C virus (HCV) infection, and routine screening is recommended. Highly effective HCV treatments for dialysis patients are newly available and cure >90% of patients in 12 weeks. Dialysis facilities should screen individuals for HCV, confirm infections, and treat or link patients to care and treatment. The New York City (NYC) Department of Health and Mental Hygiene electronically receives all positive HCV antibody and all positive and negative HCV RNA tests for NYC residents...
April 6, 2018: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/29579873/long-term-survival-and-evolution-of-the-kidney-function-for-liver-transplant-patients-who-required-postoperative-dialysis
#6
F Rosique, J B Cabezuelo, D Ferreras, M R González-Sánchez, J Ros, J A Pons, P A Cascales-Campos, F Sánchez-Bueno, R Robles, P Ramírez, P Parrilla
Patients who underwent orthotopic liver transplantation (OLT) frequently develop chronic kidney disease, with those who present postoperative acute kidney failure and require renal replacement therapy (RRT) at higher risk. The objective of the study was to assess the kidney function and long-term survival of patients who underwent OLT and required RRT during or in the immediate postoperative period. Medical records of OLT and postoperative RRT patients with over 6-month survival were reviewed between January 1, 2005, and December 31, 2015...
March 2018: Transplantation Proceedings
https://www.readbyqxmd.com/read/29546809/hcv-viraemia-in-anti-hcv-negative-haemodialysis-patients-do-we-need-hcv-rna-detection-test
#7
Nikolaos Papadopoulos, Ioannis Griveas, Eirini Sveroni, Vasiliki Argiana, Antonios Kalliaropoulos, Beatriz Martinez-Gonzalez, Melanie Deutsch
BACKGROUND: Hepatitis C virus (HCV) infection is still common among dialysis patients, but the natural history of HCV in this group is not completely understood. The KDIGO HCV guidelines of 2009 recommend that chronic haemodialysis patients be screened for HCV antibody upon admission to the dialysis clinic and every 6 months thereafter if susceptible to HCV infection. However, previous studies have shown the presence of HCV viraemia in anti-HCV-negative haemodialysis patients as up to 22%...
March 2018: International Journal of Artificial Organs
https://www.readbyqxmd.com/read/29543897/cost-effectiveness-analysis-of-elbasvir-grazoprevir-regimen-for-treating-hepatitis-c-virus-genotype-1-infection-in-stage-4-5-chronic-kidney-disease-patients-in-france
#8
Franck Maunoury, Aurore Clément, Chizoba Nwankwo, Laurie Levy-Bachelot, Armand Abergel, Vincent Di Martino, Eric Thervet, Isabelle Durand-Zaleski
OBJECTIVE: To assess the cost-effectiveness of the elbasvir/grazoprevir (EBR/GZR) regimen in patients with genotype 1 chronic hepatitis C virus (HCV) infection with severe and end-stage renal disease compared to no treatment. DESIGN: This study uses a health economic model to estimate the cost-effectiveness of treating previously untreated and treatment experienced chronic hepatitis C patients who have severe and end stage renal disease with the elbasvir-grazoprevir regimen versus no treatment in the French context...
2018: PloS One
https://www.readbyqxmd.com/read/29507971/direct-acting-antiviral-prophylaxis-in-kidney-transplantation-from-hepatitis-c-virus-infected-donors-to-noninfected-recipients-an-open-label-nonrandomized-trial
#9
Christine M Durand, Mary G Bowring, Diane M Brown, Michael A Chattergoon, Guido Massaccesi, Nichole Bair, Russell Wesson, Ashraf Reyad, Fizza F Naqvi, Darin Ostrander, Jeremy Sugarman, Dorry L Segev, Mark Sulkowski, Niraj M Desai
Background: Given the high mortality rate for patients with end-stage kidney disease receiving dialysis and the efficacy and safety of hepatitis C virus (HCV) treatments, discarded kidneys from HCV-infected donors may be a neglected public health resource. Objective: To determine the tolerability and feasibility of using direct-acting antivirals (DAAs) as prophylaxis before and after kidney transplantation from HCV-infected donors to non-HCV-infected recipients (that is, HCV D+/R- transplantation)...
April 17, 2018: Annals of Internal Medicine
https://www.readbyqxmd.com/read/29491685/nationwide-cohort-study-suggests-that-nucleos-t-ide-analogue-therapy-decreases-dialysis-risk-in-taiwanese-chronic-kidney-disease-patients-acquiring-hepatitis-b-virus-infection
#10
Yi-Chun Chen, Chung-Yi Li, Shiang-Jiun Tsai, Yen-Chun Chen
AIM: To investigate the risk of end-stage renal disease (ESRD) in hepatitis B virus (HBV)-infected patients with chronic kidney disease (CKD) with and without nucleos(t)ide analogue (NA) therapy. METHODS: This nationwide cohort study included 103444 Taiwanese CKD adults without hepatitis C virus infection from the Taiwan Longitudinal Health Insurance Database 2005 between 1997 and 2012. We identified 2916 CKD patients who acquired HBV infection and did not receive NAs (untreated cohort), and they were propensity-matched 1:4 with 11664 uninfected counterparts...
February 28, 2018: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/29445495/rituximab-therapy-for-hepatitis-c-virus-associated-cryoglobulinemic-membranoproliferative-glomerulonephritis
#11
Abhilash Koratala, Xu Zeng
Membranoproliferative glomerulonephritis associated with mixed cryoglobulinemia is the most common form of kidney disease observed in relation to hepatitis C virus (HCV) infection. Rituximab, a monoclonal antibody against CD20, is an effective treatment for severe and/or refractory HCV-related vasculitis and may evade the need for dialysis as in our patient.
February 2018: Clinical Case Reports
https://www.readbyqxmd.com/read/29405150/seroprevalence-risk-factors-and-genotype-distribution-for-hepatitis-c-infection-a-study-from-rural-hospital-in-maharashtra
#12
Satish Ramchandrra Patil, Kailash D Datkhile, M V Ghorpade, Supriya Satish Patil, Satish V Kakade
BACKGROUND AND OBJECTIVES: Hepatitis C is global health problem affecting a significant portion of the world's population. Available data in Western Maharashtra on seroprevalence, risk factors and genotype distribution are very limited. OBJECTIVES: The present study was carried out to estimate the seroprevalence, factors influencing transmission and distribution of genotype of hepatitis C virus (HCV) in a hospital-based population. MATERIALS AND METHODS: This was a cross-sectional, hospital-based study...
October 2017: Indian Journal of Medical Microbiology
https://www.readbyqxmd.com/read/29394966/factors-affecting-dermatological-manifestations-in-patients-with-end-stage-renal-disease
#13
Muhammad Anees, Ghazala Butt, Shaista Gull, Asif Nazeer, Ijaz Hussain, Muhammad Ibrahim
OBJECTIVE: To determine skin changes in patients of End Stage Renal Disease (ESRD) on maintenance hemodialysis (MHD) and factors affecting these changes. STUDY DESIGN: Cross-sectional observational study. PLACE AND DURATION OF STUDY: Nephrology Department, Mayo Hospital, Lahore in collaboration with Dermatology Department, King Edward Medical University, Lahore, from October 2015 to January 2016. METHODOLOGY: Two hundred patients who were undergoing MHD for more than three months were included in the study...
February 2018: Journal of the College of Physicians and Surgeons—Pakistan: JCPSP
https://www.readbyqxmd.com/read/29291208/hepatitis-c-infection-in-renal-transplantation-pathogenesis-current-impact-and-emerging-trends
#14
REVIEW
Sailaja Kesiraju, Praneeth Srikanti, S Sahariah
Prevalence of hepatitis C infection, which is associated with mortality and morbidity, is higher in chronic kidney disease patients on hemodialysis and transplant recipients when compared to non HCV infected patients. In addition to the conventional risk factors, HCV infection maybe an additional risk factor in the development of chronic kidney disease. HCV causes adverse effects leading to the poor long term outcome in renal transplant recipients; hepatitis C infection can cause both hepatic as well as extra hepatic complications...
September 2017: Virusdisease
https://www.readbyqxmd.com/read/29277956/kidney-transplantation-and-waitlist-mortality-rates-among-candidates-registered-as-willing-to-accept-a-hepatitis-c-infected-kidney
#15
Brittany A Shelton, Deirdre Sawinski, Shikha Mehta, Rhiannon D Reed, Paul A MacLennan, Jayme E Locke
BACKGROUND: HCV-infected (HCV+) ESRD patients derive significant survival benefit from kidney transplantation (KT) over remaining on dialysis. Given high mortality rates on dialysis and the unique ability to accept HCV+ and HCV- donor kidneys, understanding their access to KT is essential. METHODS: Three thousand nine hundred and sixty-three adult kidney-only candidates reported as willing to accept an HCV+ kidney from 2008 to 2014 were identified and assumed to be HCV+...
December 26, 2017: Transplant Infectious Disease: An Official Journal of the Transplantation Society
https://www.readbyqxmd.com/read/29259634/prevalence-of-hepatitis-c-infection-in-iranian-hemodialysis-patients-an-updated-systematic-review-and-meta-analysis
#16
REVIEW
Nahid Ramezan Ghorbani, Shirin Djalalinia, Mitra Modirian, Zahra Esmaeili Abdar, Morteza Mansourian, Armita Mahdavi Gorabi, Hamid Asayesh, Hossein Ansari, Mehrdad Kazemzadeh Atoofi, Ramin Tajbakhsh, Mehdi Noroozi, Saeid Safiri, Mostafa Qorbani
Background: Hepatitis C virus (HCV) is a major cause of liver disease and a potential cause of substantial morbidity and mortality. This study aims to provide a comprehensive evidence on HCV Infection in Iranian hemodialysis (HD) patients we conducted a systematic review. Materials and Methods: In this systematic review and meta-analysis, through a comprehensive search of literature until January of 2016, we estimated the pooled prevalence of hepatitis C infection in Iranian HD patients...
2017: Journal of Research in Medical Sciences: the Official Journal of Isfahan University of Medical Sciences
https://www.readbyqxmd.com/read/29238510/epidemiology-transmission-diagnosis-and-outcome-of-hepatitis-c-virus-infection
#17
REVIEW
Seyed Hamid Moosavy, Parivash Davoodian, Mirza Ali Nazarnezhad, Abdolazim Nejatizaheh, Ebrahim Eftekhar, Hamidreza Mahboobi
Hepatitis C infection is one of the main causes of chronic liver disorders worldwide. Nearly three percent (3%) of the world population has an HCV infection. Prevalence of HCV infection was higher in some groups such as injected drug users (IDUs) and HIV positive populations. Acute hepatitis has proven asymptomatic in most cases, and delay of diagnosis might lead to late onset of hepatocellular carcinoma and cirrhosis. Some host characteristics such as age, gender, body mass index, and viral properties are associated with HCV outcome hepatitis...
October 2017: Electronic Physician
https://www.readbyqxmd.com/read/29214477/prevalence-of-occult-hepatitis-c-virus-among-hemodialysis-patients-in-tanta-university-hospitals-a-single-center-study
#18
Ghada Abdelmoemen, Samy Abdelkader Khodeir, Sabry Abou-Saif, Abdelrahman Kobtan, Sherief Abd-Elsalam
Occult hepatitis C virus infection (OCI) is a newly defined type of infection by the chronic hepatitis virus (HCV) distinguished by the existence of HCV RNA in liver tissue and/or peripheral blood mononuclear cells (PBMCs) in patients whose plasma are devoid of both positive serology and RNA. Patients on maintenance hemodialysis evince a higher HCV prevalence than the general population due to high nosocomial transmission by the dialysis units. We investigated the prevalence of occult HCV infection in patients attending our university hemodialysis centers for maintenance hemodialysis...
February 2018: Environmental Science and Pollution Research International
https://www.readbyqxmd.com/read/29107361/race-but-not-hepatitis-c-co-infection-affects-survival-of-hiv-individuals-on-dialysis-in-contemporary-practice
#19
Deirdre Sawinski, Kimberly A Forde, Jayme E Locke, Jordana B Cohen, Joe Weldon, Justine Shults, Peter P Reese
Individuals with HIV infection are at elevated risk of developing end-stage renal disease. However, their outcomes after starting chronic dialysis in the contemporary era of widespread antiretroviral therapy are not well described. Using detailed data from a national dialysis provider, we determined HIV status by administrative codes and antiretroviral medication prescriptions, with hepatitis C virus (HCV) co-infection status provided by routinely measured serology. The survival on dialysis among 5348 individuals in the HIV+ group and 1863 HIV+ /HCV+ individuals to a HIV- /HCV- reference cohort was compared...
March 2018: Kidney International
https://www.readbyqxmd.com/read/29076048/prevalence-of-hepatitis-c-virus-infection-according-to-the-year-of-birth-identification-of-risk-groups
#20
K Neukam, E Ridruejo, P Pérez, R H Campos, A P Martínez, F A Di Lello
Hepatitis C virus (HCV) screening according to the year of birth is recommended is some countries based on epidemiological data. The aim of this study was to analyze anti-HCV prevalence among people born between 1905 and 2015 in Argentina. Patients attending a tertiary care hospital in Buenos Aires, Argentina, from 2001 to 2015, who had a determination of anti-HCV, were included. Of 22,079 patients analyzed, 1,152 (5.2%; 95% confidence interval [CI]: 4.9%-5.5%) patients showed positive anti-HCV and 729 (3.3%; 95% CI: 3...
February 2018: European Journal of Clinical Microbiology & Infectious Diseases
keyword
keyword
95472
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"